AcelRx reports Q3 EPS (94c), two estimates ($1.20)

Reports Q3 revenue $507,000, two estimates $620,000. "We have continued to reduce costs and advance the portfolio as planned. We have progressed our lead nafamostat product candidate, Niyad to prepare for a potential Emergency Use Authorization in the first half of 2023 and initiated early commercial planning to ensure we’re prepared for a potential launch next year," stated Vince Angotti, CEO of AcelRx. "Additionally, we expect to submit our ephedrine pre-filled syringe NDA by the end of this year, with the second pre-filled syringe product submission planned for the first half of next year to ensure we have multiple potential commercial products available by the end of 2023."